Abstracts tagged "Angiogenesis"

Abstract Number: 0252 • ACR Convergence 2025
Capillaroscopic Signatures in Autoimmune Rheumatic Diseases: Unveiling Patterns in Systemic Sclerosis, Polyautoimmunity, and PAH
María Paula Carrillo¹, Juan Esteban Bedoya-Loaiza¹, Claudia Ibáñez-Antequera¹, Laura Gallego¹, Alejandro Escobar¹, Adriana Rojas-Villarraga² and Jairo Cajamarca-Baron³, ¹Fundacion universitaria de ciencias de la salud, Bogota, Distrito Capital de Bogota, Colombia, ²Fundacion Universitaria de Ciencias de la salud, Bogotá, Distrito Capital de Bogota, Colombia, ³Fundacion universitaria de ciencia de la Salud, Bogota, Distrito Capital de Bogota, Colombia
Background/Purpose: Nailfold capillaroscopy is a fundamental tool in rheumatology for assessing capillary morphology, allowing the differentiation between primary and secondary Raynaud’s phenomenon, identifying risks associated…
Abstract Number: 1436 • ACR Convergence 2025
Angiogenesis Markers in Difficult to Treat Psoriatic Arthritis Patients
Devy Zisman¹, Amir Haddad², Dunia Araide³, Noa Hayat², Tal Gazitt⁴, Joy Feld⁵, Michal Aizenberg Peleg¹, Muhanad Abu-Elhija¹, Ameen Batheesh¹, Abdulla Watad⁶, Alina Simanovich¹, Nili Stein¹, Kateryna Milman² and Michal Amit Rahat¹, ¹Carmel Medical Center, Haifa, Israel, ²Carmel Medical Centre, Haifa, Israel, ³The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, HaZafon, Israel, ⁴Carmel Hospital, Haifa, Israel, ⁵Carmel and Zvulun Medical Centre, Haifa, Israel, ⁶Tel Hashomer Medical Center, Ramat Gan, Israel
Background/Purpose: Difficult to treat (D2T) psoriatic arthritis (PsA) presents a state of active inflammatory disease manifestations despite therapy with at least two biologic disease modifying…
Abstract Number: 0809 • ACR Convergence 2025
Human blood vessel organoids as a model of vasculopathy in systemic sclerosis
Yanhua Xiao¹, Xuezhi Hong¹, Langxian Zhi¹, Yi-Nan Li², Martin Regensburger³, Franz Marxreiter⁴, Boris Görg⁵, Sarah Koziel⁶, Andrea-Hermina Györfi⁷, Tim Filla⁸, Peter-Martin Bruch⁶, Philipp Tripal⁹, James Adjaye¹⁰, Sascha Dietrich¹¹, Jürgen Winkler⁴, Jörg Distler¹² and Alexandru-Emil Matei¹³, ¹Medical Faculty of Heinrich Heine University, Dusseldorf, Germany, ²University Hospital of Düsseldorf, Düsseldorf, Germany, ³Department of Stem Cell Biology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany, ⁴Department of Molecular Neurology, FAU Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany, ⁵Heinrich-Heine University, Dusseldorf, Germany, ⁶University Hospital Düsseldorf, Dusseldorf, Germany, ⁷Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁸Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁹University Hospital Erlangen, FAU Erlangen-Nürnberg, Erlangen, ¹⁰Institute for Stem Cell Research and Regenerative Medicine, University Hospital Düsseldorf, Moorenstrasse ⁵, D-⁴⁰²²⁵ Duesseldorf, Germany, Dusseldorf, Germany, ¹¹Heinrich Heine University Duesseldorf, University Hospital Duesseldorf, Duesseldorf, Germany, ¹²University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany
Background/Purpose: While several pathogenic processes involved in vasculopathy in systemic sclerosis (SSc) have been described1-3, the mechanisms that underlie the SSc microvasculopathy remain incompletely understood.…
Abstract Number: 0093 • ACR Convergence 2025
Soluble CD13 engages protease-activated receptor 4 to promote synovial inflammation and angiogenesis in rheumatoid arthritis
Chenyang Lu¹, Megan N Mattichak², Simin Xu¹, William D Brodie³, Neha Khanna², Hafsa Amin², Qi Wu², Phillip Campbell², David Fox⁴ and Pei-Suen Tsou⁵, ¹Division of Rheumatology, Department of Internal Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, Guangzhou, China (People's Republic), ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, ⁴University of Michigan, Dexter, MI, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Soluble CD13 (sCD13), the soluble form of aminopeptidase N/CD13, exhibits potent chemoattractant, angiogenic, and arthritogenic properties. While we previously identified certain G protein-coupled receptors…
Abstract Number: 0081 • ACR Convergence 2025
Trans-endothelial Trafficking of Fibroblast-like Synoviocytes Amplifies Synovial Inflammation in Rheumatoid Arthritis
Jaeyeon Kim¹, Sanaz Panahandeh², Hieu Nguyen³, Kainat Mian⁴, Hadijat Makinde⁴, Kyoung Jae Won⁵, Arminja Kettenbach³, Harris R Perlman⁴, Costantino Pitzalis⁶ and Nunzio Bottini⁷, ¹Cedars Sinai Medical Center, Los Angeles, CA, ²Cedars-Sinai Medical Center, Los Angeles, ³Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁴Northwestern University, Chicago, IL, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, ⁶QMUL, Bromley Kent, United Kingdom, ⁷Cedars Sinai Medical Center, Beverly Hills, CA
Background/Purpose: The discovery of circulating fibroblast-like synoviocyte (FLS), known as PRIME cells, in RA patients suggests that synovial FLS may enter the circulation through blood…
Abstract Number: 0053 • ACR Convergence 2025
The Integrin Inhibitor Cilengitide Targets CCN1-Mediated Angiogenesis and Reduces Disease Severity in a Preclinical Rheumatoid Arthritis Model
Jérôme Avouac¹, manon lesturgie², Virginie Gonzalez³, Sujeeba Arulananthan², Anne Cauvet³, Francoise Tilotta⁴ and Yannick Allanore⁵, ¹Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ²INSERM U¹⁰¹⁶, Paris, France, ³INSERMU¹⁰¹⁶, Paris, France, ⁴Université Paris Cité, Montrouge, France, ⁵Université Paris Cité, Paris, France
Background/Purpose: CCN1, a matricellular protein with angiogenic and immunomodulatory properties, is overexpressed in endothelial and synovial tissues of rheumatoid arthritis (RA) patients. Previous findings demonstrated…
Abstract Number: 2581 • ACR Convergence 2025
From Skin to Kidney: Neutrophil-Mediated Crosstalk Links Cutaneous Injury to Renal Inflammation and Vascular Remodeling in Lupus
Angelique Cortez¹, Lindsay Mendyka², Paola Garcia³, Elizabeth Nowak¹, Fred Kolling⁴, Lucas Salas¹, Christopher Burns⁵, Andrea Fava⁶ and Sladjana Skopelja-Gardner⁷, ¹Dartmouth College, Lebanon, NH, ²Dartmouth College, Lyme, NH, ³St. Mary's University, San Antonio, TX, ⁴Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁵Dartmouth Health, Lebanon, NH, ⁶Johns Hopkins University, Baltimore, MD, ⁷Dartmouth Geisel School of Medicine, Lebanon, NH
Background/Purpose: The majority of SLE patients are sensitive to ultraviolet light (UV), which can lead to local and systemic inflammation, including lupus nephritis (LN) flares.…
Abstract Number: 2478 • ACR Convergence 2025
Endothelial Cell Biomarker Expression Suggests Increased Cell Adhesion in Juvenile SSc, Increased Cytokine Expression in JDM, and an Intermediate Phenotype in Overlap Syndrome Patients
Daniel Barnett¹, Alyssa Rosek², Yi-Chen Chen³, Alexander Cai⁴, Deren Esencan⁵, Sophia Matossian⁶, Christine Goudsmit⁷, Haley Havrilla⁸, Anwesha Sanyal⁹, Julie Sturza¹⁰, Pei-Suen Tsou⁶, Kathryn Torok⁹ and Jessica Turnier¹¹, ¹Division of Pediatric Rheumatology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, Pittsburgh, PA, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, ANN ARBOR, MI, ⁴Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ⁵¹. Division of Pediatric Rheumatology, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, Pittsburgh, PA, ⁶University of Michigan, Ann Arbor, MI, ⁷University of Michigan, Ann Arbor, ⁸Division of Pediatric Rheumatology, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, Pittsburgh, PA, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰Division of Pediatric Rheumatology, CS Mott Children’s Hospital, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ¹¹University of Michigan, Saline, MI
Background/Purpose: Vasculopathy is a central driving clinical, histopathologic and pathogenic feature of juvenile systemic scleroderma (jSSc), juvenile dermatomyositis (JDM) and juvenile scleroderma-overlap syndrome (jOverlap). While…
Abstract Number: 1871 • ACR Convergence 2025
Examining the impact of ETV2 on altered endothelial phenotype in systemic sclerosis
Elio Carmona¹, Alyssa Rosek², Neha Khanna², Dinesh Khanna³, Amr Sawalha⁴ and Pei-Suen Tsou³, ¹Division of Pediatric Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Pittsburgh, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ³University of Michigan, Ann Arbor, MI, ⁴University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Our prior research demonstrated that epigenetic modifications are central to the pathogenesis of scleroderma (SSc)1. Using ATAC-seq, we found that chromatin accessibility was significantly…
Abstract Number: 1725 • ACR Convergence 2025
Functional NOTCH4 Variants Drive Vasculopathy and Fibrosis in Systemic Sclerosis.
Urvashi Kaundal¹, Pei-Suen Tsou², Mousumi Sahu³, Mengqi Huang⁴, Steven Boyden⁵, Curtis Woodford⁶, Daniel Shriner⁷, Sarah Safran⁸, Yuechen Zhou⁹, Xuetao Zhang⁶, Yosuke Kunishita¹⁰, Ami Shah¹¹, Maureen Mayes¹², Ayo Doumatey¹³, Amy Bentley⁷, Robyn Domsic⁴, Thomas Medsger, Jr¹⁴, Paula Ramos¹⁵, Richard Silver¹⁶, Virginia Steen¹⁷, John Varga², Vivien Hsu¹⁸, Lesley Ann Saketkoo¹⁹, Elena Schiopu²⁰, Jessica Gordon²¹, Lindsey Criswell²², Heather Gladue²³, Chris Derk²⁴, Elana Bernstein²⁵, S. Louis Bridges²¹, Victoria Shanmugam²⁶, Lorinda Chung²⁷, Suzanne Kafaja²⁸, Marcin TROJANOWSKI²⁹, Benjamin Korman³⁰, James Thomas³¹, Stefania Dell'orso³², davide Randazzo³³, Adebowale Adeyemo⁷, Elaine Remmers³⁴, Pamela Schwartzberg³⁵, Ivona Aksentijevich³⁶, Charles Rotimi⁷, Fredrick Wigley³⁷, Rong Wang⁶, Francesco Boin³⁸, Dinesh Khanna², Robert Lafyatis⁴, Daniel Kastner³⁹ and Pravitt Gourh⁴⁰, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ²University of Michigan, Ann Arbor, MI, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Utah Center for Genetic Discovery, Department of Human Genetics, University of Utah, Salt Lake City, UT, Bethesda, MD, ⁶Laboratory for Accelerated Vascular Research, Department of Surgery, University of California, San Francisco, San Francisco, CA, san francisco, CA, ⁷Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, bethesda, MD, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases, New York, NY, ⁹Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, Pittsburg, PA, ¹⁰National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Rockville, MD, ¹¹Johns Hopkins Rheumatology, Baltimore, MD, ¹²UT Health Houston Division of Rheumatology, Houston, TX, ¹³Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, bethedsa, MD, ¹⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, Verona, PA, ¹⁵Emory University School of Medicine, Atlanta, GA, ¹⁶Medical University of South Carolina, Charleston, SC, ¹⁷Georgetown University School of Medicine, Washington, DC, ¹⁸Rutgers- RWJ Medical School, South Plainfield, NJ, ¹⁹University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, ²⁰Division of Rheumatology, Medical College of Georgia at Augusta University, Augusta, GA, Augusta, GA, ²¹Hospital for Special Surgery, New York, NY, ²²NIH/NHGRI, Bethesda, MD, ²³Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²⁴University of Pennsylvania, Philadelphia, PA, ²⁵Columbia University Irving Medical Center, New York, NY, ²⁶Office of Autoimmune Disease Research, Office of Research on Women's Health, Office of the Director, National Institutes of Health, Bethesda, MD, bethesda, MD, ²⁷Stanford University, Stanford, CA, ²⁸UCLA Department of Medicine, Division of Rheumatology, Los Angeles, CA, ²⁹BOSTON UNIVERSITY SCHOOL OF MEDICINE, BOSTON, MA, ³⁰University of Rochester, Rochester, NY, ³¹NIH Intramural Sequencing Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, bethesda, MD, ³²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³³Light Imaging Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, ³⁴Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, bethesda, MD, ³⁵Cell Signaling and Immunity Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, ³⁶¹⁰⁰, Bethesda, MD, ³⁷Johns Hopkins University, Baltimore, MD, ³⁸Cedars-Sinai Medical Center, Beverly Hills, CA, ³⁹National Human Genome Research Institute, Bethesda, MD, ⁴⁰National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD
Background/Purpose: Systemic sclerosis (SSc) is characterized by vasculopathy, progressive fibrosis of skin and internal organs, and autoimmunity. Notably, African American (AA) patients with SSc exhibit…
Abstract Number: 1624 • ACR Convergence 2025
Disease activity status in Takayasu’s arteritis influences the angiogenic potential of patient-derived endothelial cells
Luciana Yamamoto de Almeida¹, Kaitlin Quinn², James Simone², Lily Dai², Benjamin Turturice², Urvashi Kaundal², Chloe Palmer², Karyssa Stonick³, davide Randazzo⁴, Carmelo Carmona-Rivera⁵ and Peter Grayson⁶, ¹National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³National Insitute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁴Light Imaging Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, ⁵Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Takayasu's arteritis (TAK) is a rare, systemic, chronic large vessel vasculitis of unknown etiology primarily affecting the aorta and its branches. Arterial damage, with…
Abstract Number: 0042 • ACR Convergence 2024
Modulating Inflammation and Angiogenesis in an Advanced 3D Rheumatoid Arthritis Synovial Tissue Model
Eva Philippon¹, Jan Piet van Hamburg¹, Lisanne van Rooijen¹, Gary Sims², Conny Van der Laken³ and Sander Tas⁴, ¹Amsterdam UMC, Amsterdam, Netherlands, ²Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ³Amsterdam UMC - location VUMC, Amsterdam, Netherlands, ⁴Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Background/Purpose: Rheumatoid Arthritis (RA) is a progressive and systemic autoimmune disorder characterized by chronic and destructive joint inflammation. Key features of RA include synovial cell…
Abstract Number: 0043 • ACR Convergence 2024
Inflammatory and Angiogenic Serum Profile of Refractory Rheumatoid Arthritis
Manon Lesturgie-Talarek¹, Virginie Gonzalez², ALICE COMBIER³, Marion THOMAS⁴, Margaux Boisson⁵, Sandrine Carves³, Sarah Wanono³, Lucie Poiroux³, Anne Cauvet¹, Sophie Hecquet⁶, Yannick Allanore⁷ and Jérôme Avouac⁸, ¹Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, ²Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, Ile-de-France, France, ³Hôpital Cochin - Université Paris Cité, Paris, France, ⁴APHP, Paris, France, ⁵Hôpital Cochin - Université Paris Cité, Paris, ⁶Cochin Hospital, Paris, France, ⁷Université Paris Cité, Paris, France, ⁸Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Despite the emergence of new therapies, a considerable proportion of individuals with rheumatoid arthritis (RA) still endure symptoms, giving rise to the concept of…
Abstract Number: 0809 • ACR Convergence 2024
The Utility of the sFlt1:PlGF Ratio to Rule out and Predict Preeclampsia in Women with Lupus
Megan Clowse¹, Kateena Addae-Konadu², Jerome Federspiel³, Jennifer Gilner², Andra James², Eugene Kovalik², Anika Lucas³, Laura Neil², Catherine Sims⁴, Amanda Snyderman², Samir Soneji² and Amanda Eudy⁵, ¹Duke University, Chapel Hill, NC, ²Duke University School of Medicine, Durham, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Knightdale, NC, ⁵Duke University, Raleigh, NC
Background/Purpose: Women with SLE have high rates of preeclampsia caused by poor placental vascularization. The FDA recently approved the ratio of two angiogenic factors, soluble…
Abstract Number: 0880 • ACR Convergence 2024
Investigating the SRPK-1-VEGF-A Alternative Splicing Pathway AsaTherapeutic Target in Arthritis
Charles Besidonne¹, Andrew Benest¹, Kim Chisholm¹, Jonathan Morris², Lucy Donaldson³, Jeanette Woolard⁴ and David Bates¹, ¹University of Nottingham, Nottingham, United Kingdom, ²University of New South Wales, New South Wales, New South Wales, Australia, ³Versus Arthritis UK, Nottingham, United Kingdom, ⁴University of Nottingham, Nottingham, England, United Kingdom
Background/Purpose: Alternative pre-mRNA splicing of Vascular Endothelial Growth Factor-A (VEGF-A) produces pro-angiogenic (VEGF-Axxxa) or anti-angiogenic (VEGF-Axxxb) isoforms that contribute to angiogenesis in inflammatory arthritis. Isoform…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].